Periodic Reporting for period 1 - SWEATPATCH (Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic Response)
Reporting period: 2024-04-01 to 2025-03-31
Breast Cancer (BC) is the most common cancer in Europe. In most cases, BC will present at a locally advanced or distant stage, which requires anticancer drugs. However, there is no guarantee that the favorable drug benefit/risk balance will align with expectations at an individual level or be maintained over time. Therefore, monitoring tumor response to treatment is critical for timely adjusting the therapeutic strategy to improve patients’ outcomes. To fulfill this unmet medical need,SWEATPATCH proposes an innovative noninvasive approach to monitor in real-time BC response to treatment, based on emerging odorous biomarkers, namely volatile organic compounds (VOCs) from sweat emanated from the breast skin. Due to their connection to breast tumor metabolism, sweat VOCs are promising candidate biomarkers for monitoring tumor response to treatment.SWEATPATCH breakthrough relies on a radically-new technology with cutting-edge straintronic microwave based on phononic metamaterials and nanomaterials chemtronics technologies to solve scientific bottlenecks for sweat VOCs analysis in the near field of cancer cells.SWEATPATCH will gather an
interdisciplinary consortium of leading experts in materials, sensors, data processing, and translational/clinical oncology, from 6 countries. The consortium will develop a groundbreaking wireless Lab-on-a-Patch to (1) monitor BC therapeutic response directly from the breast surface using a novel biocompatible flexible patch combined with specific data analysis that (2) will also be adaptable to in vitro 3D culture systems of patients’ derived organoids, a tumor model avatar created from patients’ BC, which will be used for drug screening to modelize tumor response to treatment.SWEATPATCH will convey a considerable conceptual leap that will shift the current healthcare paradigm from «one-size-fit-all» monitoring to «a smart real-time personalized monitoring»synchronized to tumor biology to reach precision oncology.
interdisciplinary consortium of leading experts in materials, sensors, data processing, and translational/clinical oncology, from 6 countries. The consortium will develop a groundbreaking wireless Lab-on-a-Patch to (1) monitor BC therapeutic response directly from the breast surface using a novel biocompatible flexible patch combined with specific data analysis that (2) will also be adaptable to in vitro 3D culture systems of patients’ derived organoids, a tumor model avatar created from patients’ BC, which will be used for drug screening to modelize tumor response to treatment.SWEATPATCH will convey a considerable conceptual leap that will shift the current healthcare paradigm from «one-size-fit-all» monitoring to «a smart real-time personalized monitoring»synchronized to tumor biology to reach precision oncology.
The SWEATPATCH project aims to develop an innovative, non-invasive method to monitor breast cancer treatment response in real time. This approach is based on detecting volatile organic compounds (VOCs) emitted from sweat on the breast skin, which are linked to tumor metabolism. These VOCs hold strong potential as biomarkers for assessing therapeutic response.
The project consortium is creating a cutting-edge wireless Lab-on-a-Patch system that will:
Monitor breast cancer treatment efficacy directly from the skin using a novel, biocompatible flexible patch integrated with advanced data analytics.
Be adaptable for use in in vitro 3D cultures derived from patient tumor organoids—personalized tumor models that will support drug screening and prediction of treatment response.
SWEATPATCH represents a significant step forward, shifting from a "one-size-fits-all" model to real-time, personalized monitoring aligned with each patient’s tumor biology, advancing precision oncology.
The Project Coordinator is responsible for overall project management, with activities outlined under WP1.
In WP2, work has started on biochemical materials. An initial study using silica gel and hydrotalcite as filter coadjuvants to reduce humidity and CO2 was completed (Task 2.1 Deliverable D1.1). The synthesis and functionalization of graphene inks have begun, with initial samples delivered to partners in WP3 (Task 2.2 ongoing). Next steps include functionalizing the inks to target VOCs identified by WP6.
In WP3, modeling and FEM simulations were conducted to design high-performance resonators based on electroacoustic waveguides and phononic crystal cavities. This includes full modeling of nanomaterials, piezoelectric transducers, and the band structure and scattering matrix (Sij) of the devices. The first sensor design was completed (Task 3.1 Deliverable D3.1) and fabrication processes have started, with simple prototype devices currently being manufactured (Task 3.2 ongoing). A measurement platform under controlled conditions is in place and ready for initial characterizations (Tasks 3.2 & 3.3).
In WP4, the initial antenna and associated electronics for wireless energy transfer were designed, fabricated, and successfully tested (Task 4.1 Deliverable D4.1). Work on additional tasks has begun.
For WP5, data analysis has started using existing raw mass spectrometry data provided by WP6 partners.
Within WP6, the study initiation package was completed (Task 6.1 Deliverable D6.1) including registration in a WHO-compliant clinical trial registry (IdRCB: 2021-A00670-41). Protocols for generating patient-derived organoids and spheroids were finalized (Deliverable D6.2). VOCs were successfully sampled using Tenax membranes applied to the tumor side (or the corresponding side for healthy controls), demonstrating the method's ability to discriminate between VOC profiles. The clinical protocol and informed consent documents are being drafted and revised.
WP7 saw the start of dissemination and communication activities, with all outputs uploaded to the project portal. Draft versions of the dissemination and communication plan, exploitation plan, and data management plan were completed.
An Ethics Advisor was appointed under WP8 to ensure all activities meet ethical requirements.
The project consortium is creating a cutting-edge wireless Lab-on-a-Patch system that will:
Monitor breast cancer treatment efficacy directly from the skin using a novel, biocompatible flexible patch integrated with advanced data analytics.
Be adaptable for use in in vitro 3D cultures derived from patient tumor organoids—personalized tumor models that will support drug screening and prediction of treatment response.
SWEATPATCH represents a significant step forward, shifting from a "one-size-fits-all" model to real-time, personalized monitoring aligned with each patient’s tumor biology, advancing precision oncology.
The Project Coordinator is responsible for overall project management, with activities outlined under WP1.
In WP2, work has started on biochemical materials. An initial study using silica gel and hydrotalcite as filter coadjuvants to reduce humidity and CO2 was completed (Task 2.1 Deliverable D1.1). The synthesis and functionalization of graphene inks have begun, with initial samples delivered to partners in WP3 (Task 2.2 ongoing). Next steps include functionalizing the inks to target VOCs identified by WP6.
In WP3, modeling and FEM simulations were conducted to design high-performance resonators based on electroacoustic waveguides and phononic crystal cavities. This includes full modeling of nanomaterials, piezoelectric transducers, and the band structure and scattering matrix (Sij) of the devices. The first sensor design was completed (Task 3.1 Deliverable D3.1) and fabrication processes have started, with simple prototype devices currently being manufactured (Task 3.2 ongoing). A measurement platform under controlled conditions is in place and ready for initial characterizations (Tasks 3.2 & 3.3).
In WP4, the initial antenna and associated electronics for wireless energy transfer were designed, fabricated, and successfully tested (Task 4.1 Deliverable D4.1). Work on additional tasks has begun.
For WP5, data analysis has started using existing raw mass spectrometry data provided by WP6 partners.
Within WP6, the study initiation package was completed (Task 6.1 Deliverable D6.1) including registration in a WHO-compliant clinical trial registry (IdRCB: 2021-A00670-41). Protocols for generating patient-derived organoids and spheroids were finalized (Deliverable D6.2). VOCs were successfully sampled using Tenax membranes applied to the tumor side (or the corresponding side for healthy controls), demonstrating the method's ability to discriminate between VOC profiles. The clinical protocol and informed consent documents are being drafted and revised.
WP7 saw the start of dissemination and communication activities, with all outputs uploaded to the project portal. Draft versions of the dissemination and communication plan, exploitation plan, and data management plan were completed.
An Ethics Advisor was appointed under WP8 to ensure all activities meet ethical requirements.